AI Unleashed: Featuring Experts from Poolbeg Pharma & CytoReason

The pharmaceutical sector continues to experience robust growth, driven by a surge in innovative research, the advent of advanced technologies, and an increasing global demand for effective healthcare solutions. This dynamic environment is fostering the development

The future of drug discovery and pharmaceutical research is being reshaped by artificial intelligence (AI), heralding a new era of speed, efficiency, and precision. AI’s potential to accelerate drug development, from molecular prediction to optimised design

Poolbeg Pharma, founded by Cathal Friel, operates with a distinct approach to funding and development. Friel, a renowned financier, has a track record of successfully launching and selling companies through Raglan Capital, his private equity vehicle.

Pharmaceutical giants like Merck KGaA are increasingly partnering with AI companies, signaling a trend in the drug development landscape where emerging technologies are adopted to expedite and improve the drug discovery process. AI promises faster and

Poolbeg Pharma plc is dedicated to the development and commercialisation of innovative medicines, particularly those targeting diseases with high unmet medical needs, including rare and orphan diseases. The company’s strategy revolves around developing its promising clinical

GLP-1 (glucagon-like peptide-1) and its receptor agonists (GLP-1RAs) have emerged as a groundbreaking class of drugs in diabetes management, particularly due to their impressive efficacy in reducing obesity, a key factor in type 2 diabetes. Jeremy

The rapid advancement of artificial intelligence (AI) is making significant strides in the pharmaceutical sector. Since its inception, this industry has embraced AI and machine learning, continuing its legacy of innovation. The integration of these technologies

The year 2020 will be remembered for its tragic events, but in its wake, companies like Poolbeg Pharma are leading efforts to prepare for future pandemics. Richard Staines from Optimum Strategic Communications interviewed Jeremy Skillington, the

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

The pharmaceutical sector is continuously evolving, with several key patents set to expire in the coming years. To ensure the development of next-generation treatments, companies must stay abreast of the latest trends. Clarivate’s annual Drugs To

New research published in the journal Drug Discovery Today reveals that drugs discovered through artificial intelligence (AI) have a significantly higher success rate in Phase I clinical trials (80-90%) compared to those discovered by humans (40-65%).

Poolbeg Pharma said it had made progress last year in expanding its treatments into new markets, with significant pipeline advancements and strategic deals. The company said it had made a strategic expansion into the treatment of

Poolbeg Pharma announced significant advances and strategic expansions in its latest financial year, most notably with POLB 001 targeting a market opportunity exceeding $10 billion in cancer immunotherapy-induced Cytokine Release Syndrome (CRS). In its 2023 fiscal

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered into an exclusive 12-month option agreement